BioNTech acquires T cell therapy-focused Neon for $67m
BioNTech has acquired Neon Therapeutics in an all stock transaction valued at $2.18 per share...
Read More...
Focus:
-
![Clovis Rubraca FDA fast track]()
FDA grants Clovis’ Rubraca fast track designation for prostate cancer
Colorado-based Clovis Oncology has received fast track designation from the US Food and Drug Administration...
Read More...
-
![Japan ViiV Dovato HIV]()
Japan approves ViiV’s two drug regimen Dovato for HIV
ViiV Healthcare’s human immunodeficiency virus (HIV) drug Dovato (dolutegravir 50mg/lamivudine 300mg) has been approved by...
Read More...
-
![MorphoSys Incyte B cell deal]()
MorphoSys and Incyte sign $900m deal for B-cell malignancies drug
Germany-based MorphoSys has announced it has signed a collaboration and license agreement with the US...
Read More...
-
![AZ Epanova CV]()
AZ to take $100m hit from ending trial of CV drug Epanova
AstraZeneca (AZ) has announced the termination of its Phase III STRENGTH trial of Epanova (omega-3...
Read More...
-
![Pfizer oncology eFFECTOR]()
Pfizer signs oncology agreement with STR-focused eFFECTOR
San Diego-based eFFECTOR has signed an exclusive worldwide license and collaboration agreement with Pfizer in...
Read More...
-
![Galen acquires POA Pharma]()
Galen acquires Nordic-based POA Pharma in multi-million pound deal
Northern Ireland-based, globally focused pharmaceutical sales and marketing firm Galen has acquired Swedish-headquartered POA Pharma...
Read More...
-
![]()
Merck collaborates on small molecule inhibitors with Taiho and Astex
Merck has signed an exclusive worldwide research collaboration and licence agreement with two Otsuka Pharmaceutical...
Read More...
-
![]()
Janssen’s esketamine nasal spray approved in the EU
The European Commission (EC) has approved Johnson & Johnson subsidiary Janssen’s Spravato (esketamine) nasal spray...
Read More...
-
![Syncona invests Freeline]()
Syncona invests $80m in Freeline’s systemic disease gene therapies
Syncona has committed to investing $80m in gene therapy-focused Freeline’s Series C financing round.
Read More...
Close
Close
Close
Go Top
